Oral pharmaceutical composition containing loxoprofen or salt thereof, and japanese valerian
The combination of loxoprofen and valerian in oral pharmaceutical compositions addresses gastric mucosal damage concerns, providing effective antipyretic and analgesic relief with reduced side effects.
Patent Information
- Application Number
- JP2024142663
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-06-11
- Filing Date
- 2024-08-23
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2040-06-10
AI Technical Summary
Existing oral pharmaceutical compositions containing loxoprofen or its salts face challenges in minimizing gastric mucosal damage, despite loxoprofen being a prodrug with less mucosal damage compared to other NSAIDs, and the effects of combining loxoprofen with valerian for gastric mucosal protection are unclear.
An oral pharmaceutical composition combining loxoprofen or its salts with valerian root, formulated in various dosage forms, effectively reduces gastric mucosal damage while maintaining antipyretic, analgesic, and anti-inflammatory effects.
The composition significantly reduces gastric mucosal damage and maintains effective antipyretic, analgesic, and anti-inflammatory properties, making it a highly safe antipyretic and analgesic agent.
Smart Images

Figure 2024161077000010 
Figure 2024161077000011 
Figure 2024161077000001
Abstract
Description
[Technical field]
[0001] The present invention relates to an oral pharmaceutical composition for antipyretic, analgesic, and anti-inflammatory purposes, which reduces gastric mucosal damage caused by loxoprofen or a salt thereof, and more particularly, to an oral pharmaceutical composition which reduces gastric mucosal damage by containing loxoprofen or a salt thereof and valerian. [Background technology]
[0002] Loxoprofen, a propionic acid-based nonsteroidal antipyretic, analgesic, and anti-inflammatory drug (hereinafter referred to as NSAIDs), is known to have antipyretic, analgesic, and anti-inflammatory effects based on the inhibitory effect on prostaglandin biosynthesis, similar to other NSAIDs. Loxoprofen is a prodrug that is absorbed from the digestive tract as an unchanged form with weak gastric mucosa irritation after oral administration and becomes an active form in the body, and is therefore known to have the characteristic of causing less gastric mucosa damage compared to other NSAIDs (see, for example, Non-Patent Document 1).
[0003] Techniques disclosed for further suppressing gastric mucosal damage by orally administering rofecoxib or a salt thereof in combination with other active ingredients include a technique for incorporating specific sugars (lactose, sucrose, maltitol, fructose, xylitol or lactitol) into rofecoxib (see Patent Document 1), a technique for incorporating an antacid (magnesium oxide) (see Patent Document 2), and a technique for incorporating the antiplasmin drug tranexamic acid (see Patent Document 3).
[0004] On the other hand, valerian is a herbal medicine obtained from the roots and rhizomes of valerian (Valeriana fauriei Briquet). Dichloromethane extract of valerian and quesoglycol diacetate, one of the main components, show sedative effects such as hexobarbital sleep extension, inhibition of spontaneous behavior in the open field test, inhibition of passive avoidance response, and inhibition of fighting response when orally administered to mice (see Non-Patent Document 2).
[0005] As mentioned above, the effects of the combined use of loxoprofen or its salts with other active ingredients have been studied, but it is not known what effect the combined oral administration of loxoprofen or its salts with valerian has on the gastric mucosal damage suppression effect. Up to now, it has been reported that, in addition to sedative, choleretic, and hypotensive effects, valerian prevents or improves wrinkles caused by heparanase activity inhibition (see Patent Document 4), that it has an effect of improving pain and insomnia when combined with acetaminophen, ethenzamide, and allylisopropylacetylurea (Patent Document 5), and that a 50% ethanol extract of valerian has an anti-stress gastric ulcer effect in mice (Non-Patent Document 2). However, there are no reports on how valerian, which has a sedative effect, affects gastric mucosal damage caused by loxoprofen or its salts, which have different causes and sites of occurrence from stress gastric ulcers. In addition, no oral composition containing loxoprofen and valerian is known, and the combined effect of the composition is unknown. [Prior art documents] [Patent documents]
[0006] [Patent Document 1] Patent No. 4585220 [Patent Document 2] Patent No. 6106727 [Patent Document 3] Patent No. 5835865 [Patent Document 4] JP2016-169238A [Patent Document 5] JP2015-189733A [Non-patent literature]
[0007] [Non-Patent Document 1] Pharmacology and Treatment Vol.16 No.2 1988 p.611-619 [Non-Patent Document 2] 17th Revised Japanese Pharmacopoeia Commentary (Hirokawa Shoten) Summary of the Invention [Problem to be solved by the invention]
[0008] Since loxoprofen is a prodrug, it is considered that gastric mucosal damage is less than other NSAIDs, but there is still a risk of gastric mucosal damage. On the other hand, it is known that valerian is effective for insomnia, but it remains unclear what kind of results will be brought about by adding valerian to gastric mucosal damage caused by loxoprofen. That is, the object of the present invention is to clarify the effect on gastric mucosal damage caused by loxoprofen when valerian is taken orally in combination with loxoprofen. The object of the present invention is to provide a new oral pharmaceutical composition containing loxoprofen, which is used as an antipyretic, analgesic, or cold treatment agent with a reduced risk of gastric mucosal damage. [Means for solving the problem]
[0009] As a result of intensive research conducted by the inventors to solve the above-mentioned problems, they discovered that the combined use of rofecoxib or a salt thereof with valerian reduces gastric mucosal damage caused by rofecoxib or a salt thereof, and that valerian has no effect on the analgesic effect of rofecoxib or a salt thereof, and thus completed the present invention.
[0010] That is, the present invention is as follows. (1) An oral pharmaceutical composition comprising lofecoxib or a salt thereof and valerian. (2) The oral pharmaceutical composition according to (1), which is used as an antipyretic, analgesic or cold remedy. (3) The oral pharmaceutical composition according to (1) or (2), which is in the form of a tablet, fine granules, capsule or liquid. (4) An oral pharmaceutical composition according to any one of (1) to (3), containing at least 1 part by weight of valerian (calculated as raw herbal drug) per 1 part by weight of rofecoxib or a salt thereof. (5) The oral pharmaceutical composition according to any one of (1) to (3), comprising 1 to 33 parts by weight of valerian (calculated as raw herbal drug) per 1 part by weight of loxoprofen or a salt thereof. Effect of the Invention
[0011] The oral pharmaceutical composition of the present invention is characterized in that it contains an effective amount of loxoprofen or a salt thereof that exerts antipyretic, analgesic or anti-inflammatory effects, while reducing gastric mucosal damage, which is a side effect of loxoprofen or a salt thereof. In other words, the oral pharmaceutical composition of the present invention is useful as a highly safe antipyretic, analgesic or cold remedy that exerts effective antipyretic, analgesic and anti-inflammatory effects and reduces gastric mucosal damage when taken. [Brief description of the drawings]
[0012] [Figure 1] Figure 1 shows the results of investigating the effects of loxoprofen sodium dihydrate alone and the combined use of loxoprofen sodium dihydrate and valerian on gastric mucosal damage. Note that the ** in the figure indicates that there is a significant difference between the group using loxoprofen sodium dihydrate in combination with valerian and the group using loxoprofen sodium dihydrate alone (p<0.01). [Diagram 2] Figure 2 shows the results of analgesic effects of vehicle, loxoprofen sodium dihydrate alone, and the combined use of loxoprofen sodium dihydrate and valerian. The ** in the figure indicates that there is a significant difference between the group treated with the combined use of loxoprofen sodium dihydrate and valerian and the group treated with loxoprofen sodium dihydrate alone (p<0.01). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0013] In the present invention, "loxoprofen or a salt thereof" refers to loxoprofen or a salt thereof (including a hydrate salt), preferably loxoprofen sodium, and more preferably loxoprofen sodium dihydrate. Loxoprofen or a salt thereof used in the present invention is listed in the 17th Edition of the Japanese Pharmacopoeia as loxoprofen sodium hydrate together with valerian.
[0014] In the present invention, the "Valeriana" that can be used is preferably that listed in the 17th revised edition of the Japanese Pharmacopoeia. Other valerian plants besides those mentioned above are also available commercially and are easily available.
[0015] Valerian used in the present invention has been used medicinally since ancient times as a single ingredient or as a Chinese herbal medicine, and the herbal powder or extract obtained according to a conventional method can be used as it is. The form of the herbal powder or extract can be a normal commercially available product or a processed product thereof. For example, a dried chopped processed product may be further finely ground into a powder (fine powder) to be used as a dry powder. The form of the extract from the herbal medicine is not particularly limited, and any form such as a dried extract, extract powder, soft extract, liquid extract, tincture containing ethanol or ethanol and water can be used. Preferred herbal medicines include extracts with a high degree of freedom in formulation, such as soft extracts (5 times concentrated), dried extract powder, etc. The extract can be obtained by extracting an active ingredient having antibacterial activity from the herbal medicine by a conventional method, for example, an extraction solvent. For the extraction solvent, for example, water, a hydrophilic solvent, or a mixture thereof is often used. Examples of the hydrophilic solvent include alcohols such as methanol, ethanol, propanol, isopropanol, butanol, isobutanol, s-butanol, t-butanol, etc.; cellosolves such as methyl cellosolve, ethyl cellosolve, etc.; ketones such as acetone, etc.; ethers such as dioxane, tetrahydrofuran, etc.; nitrogen-containing solvents such as pyridine, morpholine, acetonitrile, N,N-dimethylformamide, dimethylacetamide, N-methylpyrrolidone, etc. These hydrophilic solvents may be used alone or as a mixed solvent of two or more kinds.
[0016] The content of rofecoxib or a salt thereof in the oral pharmaceutical composition of the present invention is not limited, but the amount of the component contained in the oral pharmaceutical composition per dosage unit (single dose) for adults is preferably 10 to 180 mg, more preferably 20 to 120 mg, and even more preferably 60 to 90 mg, calculated as the anhydrous amount, and the frequency of administration is 1 to 3 times a day.
[0017] There is also no particular limitation on the content of valerian in the oral pharmaceutical composition of the present invention, but the amount of the component contained in the oral pharmaceutical composition per dosage unit (single dose) for adults is preferably 10 to 2000 mg, more preferably 20 to 1440 mg, and even more preferably 60 to 450 mg, calculated as the amount of the original herbal drug, and the frequency of administration is 1 to 3 times a day.
[0018] Furthermore, when the oral pharmaceutical composition of the present invention is a liquid formulation to be taken once a day at 50 mL, the content of rofecoxib or a salt thereof in the liquid is preferably 10 to 180 mg / 50 mL in terms of the anhydrous substance, and in the case of valerian, the content is preferably 10 to 2000 mg / 50 mL in terms of the raw herbal drug.
[0019] In the oral pharmaceutical composition of the present invention, the blending ratio of loxoprofen or a salt thereof and valerian is not particularly limited as long as the effects of the present invention are achieved, but it is preferable to contain at least 1 part by weight of valerian (in terms of crude drug) per 1 part by weight (anhydrous equivalent) of loxoprofen or a salt thereof. A more preferred blending ratio is 1-33 parts by weight of valerian (in terms of crude drug) per 1 part by weight (anhydrous equivalent) of loxoprofen or a salt thereof, more preferably 1-12 parts by weight of valerian (in terms of crude drug) per 1 part by weight (anhydrous equivalent) of loxoprofen or a salt thereof, and most preferably 1-5 parts by weight of valerian (in terms of crude drug) per 1 part by weight (anhydrous equivalent).
[0020] The oral pharmaceutical composition of the present invention can be preferably used for the purpose of suppressing fever, pain, and inflammation. Since the active ingredient, loxoprofen or a salt thereof, has antipyretic, analgesic, and anti-inflammatory effects, it can be preferably used as an analgesic and antipyretic, particularly for the pain relief of headache, menstrual pain (period pain), toothache, pain after tooth extraction, sore throat, lower back pain, joint pain, muscle pain, stiff shoulder pain, earache, bruise pain, fracture pain, sprain pain, trauma pain, etc., and for the fever reduction during chills and fever, and can also be preferably used as a cold remedy for the purpose of relieving various cold symptoms (runny nose, stuffy nose, cough, phlegm, sore throat, fever, chills, headache, sneezing, joint pain, muscle pain).
[0021] The oral pharmaceutical composition of the present invention may be in the form of a solid preparation such as a tablet (including a chewable tablet, an effervescent tablet, an orally disintegrating tablet, etc.), a troche, a drop, a hard capsule, a soft capsule, a granule, a fine granule, a powder, a pill, a dry syrup, a suppository, a cataplasm, or a plaster; a semi-solid preparation such as a lozenge, a chewing gum, a jelly, a jelly drop, a whipped cream, an ointment, a cream, a foam, an inhaler, or a nasal gel; or a liquid preparation such as a syrup, a drink, a suspension, an alcoholic beverage, a liquid, an eye drop, an aerosol, a spray, or a spray, as described in the General Provisions of Preparations of the Japanese Pharmacopoeia, 17th Edition. In the present invention, from the viewpoints of convenience of administration and manufacturing, etc., a solid preparation is preferable, and an oral administration composition selected from the group consisting of a tablet, a capsule, a pill, a granule, a powder, and a fine granule is more preferable, and a tablet or a capsule is particularly preferable. These compositions may further contain other active ingredients, as necessary, such as antitussives / expectorants, antihistamines, anti-inflammatory agents, gastrointestinal ingredients, antacids, anticholinergics, sedatives, other vitamins, and xanthine derivatives, within the scope of the present invention. If there are any contraindications for the inclusion of these ingredients, the composition may be formulated by dividing the ingredients into granules, etc.
[0022] The antitussive / expectorant may contain one or more components selected from, for example, codeine, codeine phosphate hydrate, dihydrocodeine, dihydrocodeine phosphate, dibunate sodium, dimemorphan phosphate, tipepidine citrate, tipepidine hibenzate, dextromethorphan, dextromethorphan hydrobromide hydrate, dextromethorphan phenolphthaline salt, noscapine hydrochloride, trimetoquinol hydrochloride, phenylephrine hydrochloride, pseudoephedrine hydrochloride, pseudoephedrine sulfate, l-methylephedrine hydrochloride, dl-methylephedrine hydrochloride, ambroxol hydrochloride, bromhexine hydrochloride, and the like.
[0023] As the antihistamine, for example, one or more components selected from azelastine hydrochloride, alimemazine tartrate, ebastine, epinastine hydrochloride, emedastine fumarate, oxatomide, olopatadine hydrochloride, carbinoxamine, diphenyl disulfonate, carbinoxamine maleate, d-chlorpheniramine maleate, dl-chlorpheniramine maleate, ketotifen fumarate, diphenylpyraline hydrochloride, diphenylpyraline theoclate, diphenhydramine hydrochloride, diphenhydramine salicylate, diphenhydramine tannate, triprolidine hydrochloride, tripelennamine hydrochloride, thonzylamine hydrochloride, fexofenadine, fenethazine hydrochloride, promethazine hydrochloride, promethazine, mequitazine, methdilazine hydrochloride, loratadine, etc. may be blended.
[0024] As the anti-inflammatory agent, one or more components selected from glycyrrhizinic acid and its derivatives and salts thereof (eg, dipotassium glycyrrhizinate, monoammonium glycyrrhizinate, etc.), tranexamic acid, licorice, etc., can be blended.
[0025] As the gastrointestinal drug component, one or more components selected from gefarnate, cetraxate hydrochloride, sofalcone, teprenone, methylmethionine sulfonium chloride, etc. can be blended.
[0026] Antacids include alkaline earth metal and / or earth metal basic inorganic compounds, such as magnesium silicate, magnesium aluminosilicate, magnesium aluminum silicate, magnesium oxide, magnesium hydroxide, co-precipitation product of magnesium hydroxide and aluminum potassium sulfate, magnesium carbonate, synthetic hydrotalcite, magnesium aluminometasilicate, dried aluminum hydroxide gel, synthetic aluminum silicate, magnesium alumina hydroxide, aluminum hydroxide gel, co-precipitation product of aluminum hydroxide and sodium hydrogen carbonate, mixed dried gel of aluminum hydroxide and magnesium carbonate, co-precipitation product of aluminum hydroxide, magnesium carbonate and calcium carbonate, and benzene carbonate. Examples of the inorganic salts include inorganic salts of metals selected from magnesium, aluminum and calcium, such as tonite, calcium silicate, calcium carbonate, precipitated calcium carbonate, calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate, and the like. Examples of the alkaline metal-based basic inorganic compounds include inorganic salts of metals selected from sodium and potassium, such as dry sodium carbonate, sodium hydroxide, sodium hydrogen carbonate, sodium carbonate hydrate, sodium hydrogen phosphate hydrate, anhydrous sodium monohydrogen phosphate, potassium hydroxide, potassium hydrogen carbonate, potassium carbonate, and the like. Other examples include borax and glycine, and one or more of the components selected from these may be blended. Among these, magnesium oxide, magnesium aluminometasilicate, synthetic aluminum silicate, precipitated calcium carbonate, and glycine are particularly preferred.
[0027] As the anticholinergic agent, one or more ingredients selected from scopolamine hydrobromide, Datura extract, methylscopolamine bromide, methyl-l-hyoscyamine bromide, pirenzepine hydrochloride, butylscopolamine bromide, belladonna alkaloids, belladonna extract, belladonna total alkaloids, isopropamide iodide, diphenylpiperidinomethyldioxolane iodide, Scolytsum extract, Scolytsum root, and Scolytsum root total alkaloid citrate may be blended.
[0028] As the sedative, one or more components selected from bromvalerylurea, allylisopropylacetylurea, etc. may be blended.
[0029] As for vitamins, one or more ingredients selected from vitamin A, vitamin C, vitamin B1, vitamin B2, vitamin B6, vitamin B5, vitamin B12, vitamin P, hesperidin, vitamin D, vitamin E, nicotinic acid, nicotinamide, panthenol, calcium pantothenate, sodium pantothenate, biotin, a mixture of equal parts of potassium and magnesium aspartate, inositol hexanicotinate, ursodeoxycholic acid, L-cysteine, L-cysteine hydrochloride, orotin, gamma oryzanol, calcium glycerophosphate, calcium gluconate, gluconolactone, glucuronic acid amide, sodium chondroitin sulfate, carrot, and coix seed can be blended.
[0030] As the xanthine derivative, one or more components selected from caffeine hydrate, anhydrous caffeine, sodium caffeine benzoate, and caffeine citrate can be blended.
[0031] The oral pharmaceutical composition of the present invention can be formulated according to a conventional method. Loxoprofen or a salt thereof and valerian may be formulated as the same granules to form one pharmaceutical composition. Alternatively, loxoprofen or a salt thereof and valerian may be formulated separately and then formulated into one pharmaceutical composition. For example, in the latter case, granules containing loxoprofen or a salt thereof and granules containing valerian are separately produced, and then additives (excipients, etc.) are added to the granules containing loxoprofen or a salt thereof and the granules containing valerian to produce granules, fine granules or powders. Alternatively, granules containing loxoprofen or a salt thereof and granules containing valerian may be separately produced, and then additives (excipients, lubricants, etc.) may be added to the granules containing loxoprofen or a salt thereof and the granules containing valerian, followed by tableting to produce tablets, or granules containing loxoprofen or a salt thereof and granules containing valerian may be filled into capsules to produce capsules. Alternatively, granules containing loxoprofen or a salt thereof and granules containing valerian may be separately produced, and then additives may be added between the single layer containing loxoprofen or a salt thereof and the single layer containing valerian, followed by tableting to produce multi-layer tablets. Alternatively, granules containing loxoprofen or a salt thereof and granules containing valerian may be separately produced, and then tablets containing loxoprofen or a salt thereof or tablets containing valerian may be produced, followed by tableting to produce dry-coated tablets in which tablets are embedded in the tablets.
[0032] The oral pharmaceutical composition of the present invention may be once packaged in SP packaging, PTP packaging, stick packaging, bottle packaging, etc. and stored airtight. These may then be pillow-packaged, or stored in a box or the like. The material used for the pillow packaging is not particularly limited, and may be, for example, a resin film such as a polypropylene film, a polyethylene terephthalate film, or a polyethylene film, or a resin film with aluminum foil attached thereto. If hygroscopicity is a concern, a desiccant or the like may be stored simultaneously in the bottle packaging or pillow packaging.
[0033] The formulation can be prepared by using known methods and additives as appropriate. Additives may be added as appropriate within the range that does not impair the effects of the present invention. Examples of additives include excipients, disintegrants, lubricants, coating agents, binders, flow agents, plasticizers, sugar-coating agents, gloss agents, solvents, pH regulators, colorants, flavorings, sweeteners, flavorings, flavorings, and flavorings.
[0034] Examples of excipients include crystalline cellulose, powdered cellulose, potato starch, light anhydrous silicic acid, hydrated silicon dioxide, silicon dioxide, precipitated calcium carbonate, anhydrous calcium hydrogen phosphate, magnesium oxide, calcium lactate, calcium silicate, magnesium aluminometasilicate, synthetic hydrotalcite, synthetic aluminum silicate, lactose, sucrose, D-mannitol, erythritol, glucose, fructose, and the like.
[0035] Examples of disintegrants include carmellose, carmellose calcium, croscarmellose sodium, low-substituted hydroxypropylcellulose, crospovidone, alginic acid, partially pregelatinized starch, bentonite, and the like.
[0036] Examples of lubricants include magnesium stearate, calcium stearate, talc, sucrose fatty acid esters, glycerin fatty acid esters, polyethylene glycol, and hardened oils.
[0037] Examples of coating agents include aminoalkyl methacrylate copolymers, gum arabic, ethyl cellulose, carnauba wax, carboxyvinyl polymers, magnesium stearate, shellac, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, pullulan, povidone, polyvinyl alcohol, and macrogol.
[0038] The binder may be, for example, one or more components selected from gum arabic, powdered gum arabic, agar, powdered agar, plum powder, gelatin, shellac, hydroxypropyl starch, hydroxypropyl cellulose, hypromellose, pullulan, povidone, polyvinyl alcohol, methacrylic acid copolymer L, methacrylic acid copolymer, butyl methacrylate-methyl methacrylate copolymer, methyl cellulose, etc.
[0039] The fluidizing agent may be, for example, one or more components selected from hydrous silicon dioxide, light anhydrous silicic acid, synthetic aluminum silicate, heavy anhydrous silicic acid, magnesium alumina hydroxide, calcium triphosphate, talc, magnesium aluminometasilicate, calcium hydrogen phosphate granules, etc.
[0040] As the plasticizer, one or more components selected from triethyl citrate, glycerin, glycerin fatty acid esters, medium-chain fatty acid triglycerides, triacetin, concentrated glycerin, castor oil, propylene glycol, polyoxyethylene (105) polyoxypropylene (5) glycol, polysorbate 80, macrogol 400, macrogol 600, macrogol 1500, macrogol 4000, macrogol 6000, macrogol 6000NF, glycerin monostearate, isopropyl linoleate, liquid paraffin, etc. can be blended.
[0041] The sugar-coating agent may be one or more components selected from gum arabic, powdered gum arabic, ethyl cellulose, carnauba wax, carmellose sodium, titanium oxide, stearic acid, polyoxyl 40 stearate, purified gelatin, purified shellac, refined white sugar, gelatin, shellac, talc, precipitated calcium carbonate, white shellac, white sugar, hydroxypropyl cellulose, hypromellose, pullulan, povidone, polyoxyethylene, polyvinyl alcohol, macrogol, etc.
[0042] As the glossing agent, one or more components selected from carnauba wax, refined shellac, macrogol, beeswax, etc. can be blended.
[0043] As the solvent, one or more components selected from isopropanol, ethanol, glycerin, 1,3-butylene glycol, propylene glycol, macrogol, and the like can be blended.
[0044] The pH adjuster may be one or more components selected from hydrochloric acid, acetic acid, phosphoric acid, lactic acid, citric acid, succinic acid, tartaric acid, sodium bicarbonate, sodium carbonate, sodium hydroxide, potassium hydroxide, triethanolamine, etc.
[0045] As colorants, one or more components selected from yellow iron oxide, brown iron oxide, carbon black, caramel, β-carotene, licorice extract, black iron oxide, titanium oxide, yellow ferric oxide, ferric oxide, ferric oxide-glycerin suspension, food blue No. 2 aluminum lake, food yellow No. 4 aluminum lake, sodium copper chlorophyllin, riboflavin, riboflavin butyrate, riboflavin sodium phosphate, green tea powder, rose oil, etc. may be blended.
[0046] Flavoring agents include sodium chloride, Phellodendron bark powder, Phellodendron extract, Coptis chinensis, Coptis chinensis powder, orange, orange oil, cocoa powder, fructose, caramel, licorice, licorice extract, licorice powder, xylitol, calcium citrate, citric acid hydrate, sodium citrate hydrate, L-glutamic acid, sodium L-glutamate, grapefruit extract, brown sugar, cinnamon powder, cinnamon oil, saccharin, sodium saccharin hydrate, Japanese pepper powder, tartaric acid, D-tartaric acid, potassium hydrogen tartrate, DL-sodium tartrate, and ginger. It can contain one or more ingredients selected from the following: sucralose, stevia extract, purified stevia extract, Swertia jasmine, D-sorbitol, tannic acid, clove oil, tincture, chili pepper, chili pepper powder, spruce powder, trehalose hydrate, bittern powder, plum extract, fructooligosaccharides, powdered sugar, peppermint powder, D-mannitol, dl-menthol, l-menthol, menthol powder, ryunou, ryunou powder, green tea powder, DL-malic acid, DL-sodium malate, lemon oil, rose oil, etc.
[0047] As sweeteners, one or more ingredients selected from aspartame, acesulfame potassium, amacha, amacha powder, reduced maltose syrup, licorice, licorice extract, licorice powder, xylitol, dipotassium glycyrrhizinate, disodium glycyrrhizinate, saccharin, sodium saccharin hydrate, sucralose, stevia extract, purified stevia extract, refined white sugar, fructose, white sugar, maltitol, D-mannitol, erythritol, etc. may be blended.
[0048] The flavoring may be one or more ingredients selected from orange flavor, guarana extract, sweet orange, strawberry, brown sugar flavor, strawberry flavor, cherry flavor, banana powder flavor, peach essence, fruit essence, peppermint, melon powder flavor, l-menthol, peppermint oil, etc.
[0049] Flavoring agents and fragrances include: fennel powder, fennel oil, ethyl vanillin, orange, orange extract, orange essence, orange oil, chamomile oil, caramel, licorice powder, d-camphor, dl-camphor, cinnamon powder, cinnamon oil, citronella oil, sugar flavor, spearmint oil, cherry flavor, clove oil, chili flavor, spruce tincture, spruce oil, pine oil, peppermint oil, vanilla flavor, vanillin, bitter essence, and Vitabase. It can contain one or more ingredients selected from the following: Himalayan cedar oil, fruit flavor, flavor G1, hesperidin peppermint essence, bergamot oil, vermouth flavor, d-borneol, dl-borneol, matcha, mixed flavor, mint flavor, dl-menthol, l-menthol, eucalyptus oil, lavender oil, ryunou, ryunou powder, lemon powder, lemon oil, rose water, rose oil, and peppermint oil.
[0050] These additives are not limited to those listed above, and one of these may be used alone or two or more of them may be used in combination.
[0051] The present invention will be explained in more detail below by giving test examples and formulation examples, but is not limited to these examples. EXAMPLES
[0052] (Formulation Example 1) Capsules [Table 1]
[0053] The above ingredients and amounts are taken and capsules are produced in accordance with the "Capsules" section of the Japanese Pharmacopoeia General Provisions for Preparations.
[0054] (Formulation Example 2) Tablets [Table 2]
[0055] The above ingredients and amounts are taken and tablets are prepared in accordance with the "Tablets" section of the Japanese Pharmacopoeia General Provisions for Preparations. If desired, a coating may be applied.
[0056] (Formulation Example 3) Tablets [Table 3]
[0057] The above ingredients and amounts are taken and tablets are prepared in accordance with the "Tablets" section of the Japanese Pharmacopoeia General Provisions for Preparations. If desired, a coating may be applied.
[0058] (Formulation Example 4) Tablets [Table 4]
[0059] The above ingredients and amounts are taken and tablets are prepared in accordance with the "Tablets" section of the Japanese Pharmacopoeia General Provisions for Preparations. If desired, a coating may be applied.
[0060] (Formulation Example 5) Granules [Table 5]
[0061] The above ingredients and amounts are taken and granules are produced in accordance with the "Granules" section of the Japanese Pharmacopoeia General Provisions for Preparations. If desired, a coating may be applied.
[0062] (Test Example 1) Gastric mucosal damage test (1) Test substance The loxoprofen sodium dihydrate used was manufactured by Daiichi Sankyo Chemical Pharma Co., Ltd. Valerian (Valeriana Extract-T; raw herbal drug equivalent ratio 5:1) was manufactured by Nippon Funa Yakuhin Co., Ltd. These test substances were prepared by suspending tragacanth (manufactured by SIGMA) in a 0.5% tragacanth solution dissolved in water for injection (manufactured by Otsuka Pharmaceutical Factory Co., Ltd.).
[0063] (2) Animals used Six-week-old Crl:CD male rats (Japan SLC) were used after a five-day quarantine period and three days of acclimation. The animals were individually housed in a rat breeding room with a controlled temperature of 20-26°C, humidity of 40-70%, and lighting hours of 6-6 p.m. The animals were allowed free access to solid food (Oriental Yeast Co., Ltd. solid rat feed, CRF-1) and tap water, and animals with good general symptoms such as good fur and weight gain were selected for use in the study.
[0064] (3) Test method The test substance was orally administered to rats that had been fasted for 18 hours or more using a disposable polypropylene syringe (Terumo) equipped with a disposable oral probe for rats (Fuchigami Kikai).The test substance was used while stirring using a magnetic stirrer. Four hours after administration of the test substance, the animals were euthanized by cervical dislocation under light anesthesia with isoflurane, and the stomach was promptly removed and filled with 10 mL of physiological saline, and then immersed in 1% formalin and fixed until the next day. The fixed stomach was incised along the greater curvature, and the length of the gastric mucosal lesion was measured using a digital caliper. The length of the gastric mucosal lesion in each individual was calculated by measuring the major axis and summing them (total lesion length).
[0065] (4) Test results Table 5 and Figure 1 show the sum of the lengths of gastric mucosal lesions in loxoprofen sodium (anhydrous equivalent) (LOX) and valerian (LOX + valerian group). The figures in parentheses indicate the dosage of each test drug in mg / kg (valerian indicates the amount equivalent to the original herbal drug), and the results are for n=5 in each group. Statistical analysis was performed by t-test for each group, and the inhibition rate (%) was calculated from the obtained sum of the lengths of gastric mucosal lesions using the following formula.
[0066]
number
[0067] [Table 6] **Significant difference compared to LOX(80) (p<0.01) L stands for low dose and H stands for high dose.
[0068] As shown in Table 6 and Figure 1, when loxoprofen sodium dihydrate (LOX) was administered in combination with valerian, low doses of valerian (89 mg / kg in raw drug equivalent) tended to reduce gastric mucosal damage caused by loxoprofen, while high doses of valerian (355.5 mg / kg in raw drug equivalent) significantly reduced gastric mucosal damage caused by loxoprofen.
[0069] (Test Example 2) Analgesic effect test (1) Test substance The loxoprofen sodium dihydrate used was manufactured by Daiichi Sankyo Chemical Pharma. Valerian (Valerian powder) was manufactured by Nippon Funa Yakuhin. These test substances were prepared by suspending them in a medium, which was a 0.5% CMC-Na solution prepared by dissolving sodium carboxymethylcellulose (CMC-Na) (manufactured by Kanto Chemical) in water for injection (manufactured by Otsuka Pharmaceutical Factory).
[0070] (2) Animals used Four-week-old Crl:CD male rats (Japan SLC) were used after an 8-day quarantine period and acclimatization. The animals were individually housed in a rat breeding room with a controlled temperature of 19-25°C, humidity of 30-70%, and lighting time of 8-8 p.m. The animals were allowed free access to solid food (solid rat feed made by Nippon Nosan Kogyo, Lab MR Stock) and tap water, and animals with good general symptoms such as fur and weight gain were selected for use in the study.
[0071] (3) Test method The test substance was orally administered to rats that had been fasted for 12 hours or more using a disposable polypropylene syringe (Terumo) with a disposable rat oral probe (Fuchigami Kikai) attached 30 minutes before administration of the inflammatory substance. 30 minutes after administration of the substance, 0.7% acetic acid saline was filled into a syringe (Terumo) with a 26G needle (Terumo) and administered intraperitoneally as the inflammatory substance. The period from 10 to 20 minutes after administration of the inflammatory substance was recorded with a video camera, and the number of writhing symptoms that occurred within 10 minutes was measured using a PLUS HAND COUNTER (Plus).
[0072] (4) Test results Table 6 and Figure 2 show the average number of writhing episodes (per 10 minutes) for loxoprofen sodium (calculated as anhydrous) (LOX) and valerian (LOX + valerian group). The figures in parentheses indicate the dose of each test drug in mg / kg (for valerian, the amount of the original herb) and the results are for n=5 for each group. For statistical analysis, a t-test was performed for each group, and the inhibition rate of writhing episodes (%) was calculated from the obtained number of writhing episodes using the following formula.
[0073]
number
[0074] [Table 7] **Significant difference compared to the control group (p<0.01) No significant difference between LOX(18) and LOX(18)+Valeriana(75)
[0075] As shown in Table 7 and Figure 2, analgesic effects were observed in the loxoprofen sodium dihydrate (LOX) group and the combined valerian group (LOX (18) + valerian (75)) (valerian was 75 mg / kg in raw herbal dose), but there was no statistically significant difference between the two groups, indicating that valerian does not affect the analgesic effects of loxoprofen.
[0076] From Table 6, Table 7, Figure 1, and Figure 2, it was found that the combination of loxoprofen with valerian significantly reduces gastric mucosal damage without affecting the analgesic effect of loxoprofen. Until now, the effect of the combined use of loxoprofen and valerian on gastric mucosal damage was unknown, and the results obtained in Test 1 were unexpected.
[0077] Taking the dosage ratio of loxoprofen sodium to valerian (Valerian / LOX) in the gastric mucosal damage test and the analgesic effect test, the dosage ratio in the gastric mucosal damage test was 4.44 (high dose of valerian) and the dosage ratio in the analgesic effect test was 4.17, which are almost the same. Since valerian had almost no effect on the analgesic effect of loxoprofen sodium in the analgesic effect test, it is unlikely that the dosage ratio in the gastric mucosal damage test will have an effect that weakens the analgesic effect of loxoprofen sodium. In other words, valerian is thought to suppress gastric mucosal damage without affecting the analgesic effect of loxoprofen sodium. [Industrial Applicability]
[0078] The oral pharmaceutical composition of the present invention containing loxoprofen or a salt thereof and valerian is extremely useful since it significantly inhibits gastric mucosal damage caused by loxoprofen, thereby reducing the rate of side effects. The oral pharmaceutical composition of the present invention is preferably used as an antipyretic or analgesic, particularly for pain relief from headache, menstrual pain (period pain), toothache, pain after tooth extraction, sore throat, lower back pain, joint pain, muscle pain, stiff shoulder pain, earache, bruise pain, fracture pain, sprain pain, trauma pain, etc., and for fever reduction during chills and fever, and is also preferably used as a cold remedy for relieving various cold symptoms (runny nose, stuffy nose, cough, phlegm, sore throat, fever, chills, headache, sneezing, joint pain, muscle pain).
Claims
1. Contains loxoprofen or a salt thereof and valerian. An oral pharmaceutical composition for reducing gastric mucosal damage caused by rofecoxib.
2. The oral pharmaceutical composition according to claim 1, further comprising one or more selected from the group consisting of antitussives / expectorants, antihistamines, anti-inflammatory agents, gastrointestinal drug components, antacids, anticholinergic agents, sedatives, vitamins, and xanthine derivatives.
3. 3. The oral pharmaceutical composition according to claim 1, which is used as an antipyretic, analgesic, or cold remedy.
4. 3. The oral pharmaceutical composition according to claim 1 or 2, which is in the form of a tablet, fine granules, capsule or liquid.
5. 3. The oral pharmaceutical composition according to claim 1, comprising at least 1 part by weight of valerian (calculated as raw herbal medicine) per 1 part by weight of rofecoxib or a salt thereof.
6. 3. The oral pharmaceutical composition according to claim 1, which contains 1 to 33 parts by weight of valerian (calculated as raw herbal medicine) per 1 part by weight of loxoprofen or a salt thereof.
7. 3. The oral pharmaceutical composition according to claim 2, further comprising an antacid, the antacid being one or more selected from the group consisting of magnesium silicate, magnesium aluminosilicate, magnesium aluminum silicate, magnesium oxide, magnesium hydroxide, a co-precipitation product of magnesium hydroxide and aluminum potassium sulfate, magnesium carbonate, synthetic hydrotalcite, magnesium aluminometasilicate, dried aluminum hydroxide gel, synthetic aluminum silicate, magnesium alumina hydroxide, aluminum hydroxide gel, a co-precipitation product of aluminum hydroxide and sodium bicarbonate, a mixed dry gel of aluminum hydroxide and magnesium carbonate, a co-precipitation product of aluminum hydroxide, magnesium carbonate and calcium carbonate, bentonite, calcium silicate, calcium carbonate, precipitated calcium carbonate, calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate, dried sodium carbonate, sodium hydroxide, sodium bicarbonate, sodium carbonate hydrate, sodium hydrogen phosphate hydrate, anhydrous sodium monohydrogen phosphate, potassium hydroxide, potassium bicarbonate, potassium carbonate, borax, and glycine.
8. 3. The oral pharmaceutical composition according to claim 2, further comprising a sedative, the sedative being one or two selected from the group consisting of bromvalerylurea and allylisopropylacetylurea.
Citation Information
Patent Citations
Valerian preparation and preparation method thereof
CN102526135A
Selective cox-2 inhibition by edible plant extracts
JP2004532811A
Loxoprofen-containing pharmaceutical composition
JP2011140486A
Oral pharmaceutical composition containing loxoprofen or salt thereof and vitamin b12
JP2018012695A
Manufacture of lithium battery with lead body
JP1983035865A
